Judith Anderton

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

Suzanne I.S. Mosely, John E. Prime, Richard C.A. Sainson et al. · Cancer Immunology Research · 2016 · 407 citations

Immunology, Immunoediting, Immunotherapeutic Drug Discovery +21

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

D. Mark Hickinson, Teresa Klinowska, Georgina Speake et al. · Clinical Cancer Research · 2010 · 118 citations

Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors

Bernard Barlaam, Judith Anderton, Peter Ballard et al. · ACS Medicinal Chemistry Letters · 2013 · 36 citations · Full text

Her3 Receptors, Molecular Biology, Tumor Biology +18

A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression

Sarah B. Gitto, Margaret Whicker, Gareth Davies et al. · Clinical Cancer Research · 2023 · 28 citations · Full text